Peter Greenleaf - 10 Jun 2021 Form 4 Insider Report for ANTARES PHARMA, INC. (ATRS)

Role
Director
Signature
/s/ Lisa M. Kallebo as attorney-in-fact for Peter Greenleaf
Issuer symbol
ATRS
Transactions as of
10 Jun 2021
Transactions value $
$112,498
Form type
4
Filing time
14 Jun 2021, 18:22:12 UTC
Previous filing
12 May 2021
Next filing
10 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATRS Common Stock Award $112K +25.5K +46.97% $4.42 79.6K 10 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATRS Stock Option (right to buy) Award $0 +48.5K $0.00 48.5K 10 Jun 2021 Common Stock 48.5K $4.42 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest one year from the grant date.
F2 Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan.
F3 The options vest and become exercisable one year from the grant date.